StockNews.AI
HRTX
StockNews.AI
119 days

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

1. Heron Therapeutics is hosting a Q1 2025 financial results call. 2. The call is scheduled for May 6, 2025, at 8:00 a.m. ET. 3. Recent business highlights will be discussed during the conference.

Earnings
+2.33%Current Return
VS
+1.59%S&P 500
$2.1504/22 04:07 PM EDTEvent Start
$2.204/23 10:51 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The announcement about a routine earnings call typically does not influence share prices significantly. Historical context shows that financial results have more impact than the announcement itself.

How important is it?

Earnings calls can temporarily increase stock volatility but lack robust market-moving implications.

Why Short Term?

The upcoming conference call may create some short-term interest but lacks significant substance to drive long-term trends.

Related Companies

AMGNMRK
, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call. About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com. Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira DuarteExecutive Vice President, Chief Financial OfficerHeron Therapeutics, Inc.[email protected]858-251-4400 SOURCE Heron Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News